In support of this, our group and others have shown that 1) acute treatment with olanzapine increases circulating glucagon (Townsend et al., 2018), (Shamshoum et al., 2019), (Shamshoum et al., 2022), (Shamshoum et al., 2021a), 2) the hyperglycemic effects of olanzapine are absent in glucagon receptor knockout mice (Medak et al., 2019), (Shamshoum et al., 2019), and 4) suppressing pancreatic secretions with somatostatin blocked olanzapine-induced hyperglycemia ( GLP1 is a hormone which can reduce the glucagon:insulin ratio and is higher in female mice, a model of protection from olanzapine-induced hyperglycemia, compared to male or ovariectomized mice (Medak et al., 2019), (Handgraaf et al., 2018)
For patients and clinicians following this area, the most reliable sources of updated information include the MHRA (gov.uk/mhra), NICE (nice.org.uk), NHS England , and peer-reviewed publications
Herrou, Julia, et al
Well be updating this page regularly as new peer-reviewed research, market developments, and industry insights emerge, so check back often to see whats new and what the science is saying next
13 Q3
